{"id":410480,"date":"2025-11-20T00:30:00","date_gmt":"2025-11-19T23:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=410480"},"modified":"2025-10-23T14:43:41","modified_gmt":"2025-10-23T12:43:41","slug":"long-term-data-on-cftr-modulators-in-children-with-cystic-fibrosis","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/long-term-data-on-cftr-modulators-in-children-with-cystic-fibrosis\/","title":{"rendered":"Long-term data on CFTR modulators in children with cystic fibrosis"},"content":{"rendered":"\n

Cystic fibrosis (CF) is one of the most common congenital metabolic diseases in Europe. The treatment options for CF patients have expanded significantly in recent years. CFTR modulators improve the function of the defective CFTR protein and are therefore the first drugs with at least partial causal effect in CF. In an open label Phase IIIb extension study, the use of the combination therapy of ivacaftor, elexacaftor and tezacaftor was investigated in 6-11-year-old children over a period of 96 weeks. <\/strong><\/p>\n\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

Cystic fibrosis (CF) is one of the most common congenital metabolic diseases in Europe. The treatment options for CF patients have expanded significantly in recent years. CFTR modulators improve the……... <\/p>\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":410482,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Study report","footnotes":""},"category":[11508,11297,11437,11455,11548,11503],"tags":[15477,12139,21471,83202,83200,83204],"powerkit_post_featured":[],"class_list":["post-410480","post","type-post","status-publish","format-standard","has-post-thumbnail","category-education","category-general-internal-medicine","category-pediatrics","category-pneumology","category-rx-en","category-studies","tag-cf-en","tag-cftr-modulators","tag-cystic-fibrosis-en-2","tag-elexacaftor-en","tag-ivacaftor-en","tag-tezacaftor-en","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-26 06:15:46","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":410481,"slug":"donnees-a-long-terme-sur-les-modulateurs-de-cftr-chez-les-enfants-atteints-de-mucoviscidose","post_title":"Donn\u00e9es \u00e0 long terme sur les modulateurs de CFTR chez les enfants atteints de mucoviscidose","href":"https:\/\/medizinonline.com\/fr\/donnees-a-long-terme-sur-les-modulateurs-de-cftr-chez-les-enfants-atteints-de-mucoviscidose\/"},"it_IT":{"locale":"it_IT","id":410403,"slug":"dati-a-lungo-termine-sui-modulatori-cftr-nei-bambini-con-fibrosi-cistica","post_title":"Dati a lungo termine sui modulatori CFTR nei bambini con fibrosi cistica","href":"https:\/\/medizinonline.com\/it\/dati-a-lungo-termine-sui-modulatori-cftr-nei-bambini-con-fibrosi-cistica\/"},"pt_PT":{"locale":"pt_PT","id":410329,"slug":"dados-a-longo-prazo-sobre-os-moduladores-cftr-em-criancas-com-fibrose-quistica","post_title":"Dados a longo prazo sobre os moduladores CFTR em crian\u00e7as com fibrose qu\u00edstica","href":"https:\/\/medizinonline.com\/pt-pt\/dados-a-longo-prazo-sobre-os-moduladores-cftr-em-criancas-com-fibrose-quistica\/"},"es_ES":{"locale":"es_ES","id":410340,"slug":"datos-a-largo-plazo-sobre-los-moduladores-del-cftr-en-ninos-con-fibrosis-quistica","post_title":"Datos a largo plazo sobre los moduladores del CFTR en ni\u00f1os con fibrosis qu\u00edstica","href":"https:\/\/medizinonline.com\/es\/datos-a-largo-plazo-sobre-los-moduladores-del-cftr-en-ninos-con-fibrosis-quistica\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/410480","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=410480"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/410480\/revisions"}],"predecessor-version":[{"id":410483,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/410480\/revisions\/410483"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/410482"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=410480"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=410480"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=410480"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=410480"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}